LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers

Chen Chen,Wei-Ran Liu,Bin Zhang,Lian-Min Zhang,Chen-Guang Li,Chang Liu,Hua Zhang,Yan-Song Huo,Yu-Chen Ma,Peng-Fei Tian,Qi Qi,Jing-Jing Li,Zhe Tang,Zhen-Fa Zhang,Giuseppe Giaccone,Dong-Sheng Yue,Chang-Li Wang

DOI: https://doi.org/10.1016/j.canlet.2020.05.009

IF: 9.756

2020-08-01

Cancer Letters

Abstract:<p>First-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib have significant activity in NSCLC patients with activating EGFR mutations. However, EGFR-TKI resistance inevitably occurs after approximately 12 months of treatment. Acquired mechanisms of resistance, other than secondary mutations in EGFR (T790 M) which account for 50–60%, are less well understood. Here, we identified lncRNA H19 as a significantly downregulated lncRNA in <em>vitro</em> models and clinical specimens with acquired EGFR-TKI resistance, H19 knockdown or overexpression conferred resistance or sensitivity, respectively, both in vitro and <em>in vivo</em> models. H19 downregulation contributed to erlotinib resistance through interaction and upregulation of PKM2, which enhanced the phosphorylation of AKT. AKT inhibitors restored the sensitivity of erlotinib-resistant cells to erlotinib. In EGFR-mutant patients treated with EGFR-TKIs, low H19 levels were associated with a shorter progression-free survival (PFS) (<em>P</em> = 0.021). These findings revealed a novel mechanism of low-level H19 in the regulation of erlotinib resistance in EGFR-mutant lung cancers. Combination of AKT inhibitors and EGFR-TKIs could be a rational therapeutic approach for some subgroups of EGFR-mutant lung cancer patients.</p>

oncology